UNITED STATES OF AMERICA **DECLARATION AND POWER OF ATTORNEY** JAN 1 7 2002 FOR PATENT APPLICATION As a below harmed inventor(s 1/We hereby declare that: My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s). I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled: POLYPEPTIDES OF THE "BASIC HELIX-LOOP-HELIX" BHLH FAMILY, CORRESPONDING NUCLEIC ACID SEQUENCES and the specification of which is attached hereto (Attorney Docket No. was filed on June 16, 2000 as U.S. Application Number 09/595,947 (check one) and was amended on (if applicable). was described and claimed in PCT Int'l Application Number filed on and as amended under PCT Article 19 on (if any). I/We hereby state that I/We have reviewed and understand the contents of the above identified specification, including the claims as amended by any amendment referred to above. I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 C.F.R. 1.56. Ø I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one other country other than the United States of America, listed below and having a filing date before that of the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed: FR96/15651 19 December 1996 Foreign France Priority: Number Country Day/Month/Year Filed PCT/FR97/02368 Prior 19 December 1997 Foreign Day/Month/Year Filed Number Country Appln(s): I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional application(s) listed below: Number Filing Date \boxtimes I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States application(s) or

I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States application(s) or international application designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

09/331,356 Application Serial No. 19 December 1997

Filing Date

Abandoned

Status (Patented, Pending)

I/We hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as my/our attorneys and/or agents with full power to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Customer No.: 005487 Send correspondence to:

William C. Coppola

Aventis Pharmaceuticals Products Inc.

Rt. 202-206 /Patent Department Bridgewater, New Jersey 08807

Direct Telephone Calls to: 908-231-4854

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States code §1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

inventors(s): Additional names and signatures are attack	ched.
1. Full name: Christine ICARD-LIEPKALNS	2. Full name: Jacques MALLET
Signature: Christine Toard Lepkalns	Signature: Jacque Moller
Date: 10/10/2001	Date: 10/13/0/ (cov)
Country of Citizenship: France	Country of Citizenship: France
Residence: France	Residence: France
(City and State/City and Country only)	(City and State/City and Country only)
P. O. Address: 2 bis rue Foisnard	P. O. Address: 18 rue Charcot
91410 Saint Cyr S/S Dourdan, France	75013 Paris, France
3. Full name: Philippe RAVASSARD	4. Full name:
Signature: Philippe Ravassard	Signature:
Date: 10/10/2001	Date:
Country of Citizenship: France	Country of Citizenship:
Residence: France	Residence:
(City and State/City and Country only)	Residence: (City and State/City and Country only)
P. O. Address: 25 rue Ruhmkorf 75017 Paris, France	P. O. Address:
5. Full name:	6. Full name:
Signature:	Signature:
Date:	Date:
Country of Citizenship:	Country of Citizenship:
Residence: (City and State/City and Country only)	Residence:
(City and State/City and Country only)	Residence:(City and State/City and Country only)
P. O. Address:	P. O. Address:
7. Full name:	8. Full name:
Signature:	Signature:
Date:	Date:
Country of Citizenship:	Country of Citizenship:
Residence: (City and State/City and Country only)	Residence:(City and State/City and Country only)
(City and State/City and Country only)	(City and State/City and Country only)
P. O. Address:	P. O. Address:

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code EMC-G1
Bridgewater, NJ 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626
Docket No. ST96042A